Vivodyne Raises $40M to Transform Drug Development with AI-Powered Human Tissue Testing

Vivodyne, a company pioneering an exclusively human-focused preclinical testing process, has announced $40 million in Series A funding led by Khosla Ventures. The round included participation from new investors Lingotto Investment Management, Helena Capital, and Fortius Ventures, alongside existing investors Kairos Ventures, CS Ventures, Bison Ventures, and MBX Capital.

The funding addresses a critical challenge in pharmaceutical development: the staggering near 95% failure rate of therapies that show promise in animal models during preclinical testing but ultimately fail in human clinical trials. This high failure rate represents what the industry calls the preclinical "valley of death," highlighting a fundamental flaw in traditional drug development where therapies are optimized for animal biology without human-specific refinement.

Vivodyne's platform directly tackles this problem by enabling large-scale testing on lab-grown, fully-functional human tissues. The company's sophisticated robotics and AI approach allows for the same refinement process traditionally done in animals but on complex human tissues, aiming to produce "people-ready" drug candidates for the first time.

"Vivodyne is fundamentally changing how drugs move from the lab bench to human trials," said Andrei Georgescu, Ph.D., CEO and co-founder of Vivodyne. "A model that is only predictive 5% of the time isn't a model. We're redefining success in drug discovery by overcoming the limitations that have stalled scientific progress for decades."

The company's technology enables unprecedented scale in human tissue analysis. Vivodyne produces human multi-omic data, including imaging, single-cell transcriptomics, and proteomics from more than 10,000 independent human-tissue experiments per robotic run. These lab-grown tissues are notably a thousand times larger than typical organoids, allowing for detailed, functional analyses of human drug responses that can recapitulate the complexity of human disease.

"Pharma has waited decades for scalable human data before clinical trials. We're now generating data from tens of thousands of complex human tissues, capturing immune responses and disease states that were previously inaccessible. This unprecedented scale and resolution unlock entirely new avenues for drug development," Georgescu added.

The platform's fully automated robotic workflow ensures reproducibility at an AI-scale throughput, reportedly generating more reliable, human-relevant data annually than all U.S. clinical trials combined. This capability positions Vivodyne to meet the surging demand from global pharmaceutical clients, particularly as regulatory bodies shift away from less-predictive animal models.

The $40 million financing will enable significant expansion of Vivodyne's operations, including the opening of a new 23,000-square-foot fully robotic laboratory at Genesis Marina in South San Francisco. This facility will substantially increase the company's preclinical human testing capacity, responding to growing demand that has been further spurred by recent commitments from the FDA and NIH to move away from animal models in drug development.

Click here for the original news story.